Autoimmune disorders in patients with hairy cell leukemia: are they more common than previously thought?

Dasanu, Constantin A; Bergh, Magali Van den; Pepito, Donna; Argote, Juliana Alvarez

doi:10.1185/03007995.2014.971358

Cited by 13 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, there was also a declaration bias regarding infections and autoimmune diseases. Indeed, the incidence of autoimmune complications was ten times lower than that reported in the literature (2.5% versus 25%) [54][55][56] . Moreover, we had no information about the proportion of HCLv patients, who have a worse prognosis than HCL patients.…”

Section: Discussionmentioning

confidence: 53%

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

et al. 2020

View full text Add to dashboard Cite

In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the occurrence of second malignancies during follow-up. The median age was 59 years. In total, 208 patients (75%) were treated with purine analogs (PNAs), either cladribine (159) or pentosatin (49), as the first-line therapy. After a median follow-up of 127 months, the median overall survival was 27 years, and the median relapse-free survival (RFS) was 11 years. The cumulative 10-year relapse incidence was 39%. In patients receiving second-line therapy, the median RFS was 7 years. For the second-line therapy, using the same or another PNA was equivalent. We identified 68 second malignancies in 59 patients: 49 solid cancers and 19 hematological malignancies. The 10-year cumulative incidences of cancers, solid tumors, and hematological malignancies were 15%, 11%, and 5.0%, respectively, and the standardized incidence ratios were 2.22, 1.81, and 6.67, respectively. In multivariate analysis, PNA was not a risk factor for second malignancies. HCL patients have a good long-term prognosis. PNAs are the first-line treatment. HCL patients require long-term follow-up because of their relatively increased risk of second malignancies.

show abstract

Section: Discussionmentioning

confidence: 53%

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Since 1990, relative survival has been similar to that of the background population among patients diagnosed before the age of 60 years, and has now improved to some 90%, even among elderly people (Dinmohamed et al , ). An increased risk of SPCs in HCL patients has been reported for HL, NHL and thyroid cancer, for which HCL‐related immunological impairment was suggested to contribute (Hisada et al , ; Cornet et al , ; Dasanu et al , ).…”

mentioning

confidence: 99%

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia

et al. 2019

View full text Add to dashboard Cite

Summary Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi‐directional analyses in which relative risks (RRs) were calculated for any SPCs in patients with chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy cell leukaemia (HCL) and the risks of these leukaemias as SPCs. After CLL, RRs were significant for 20 SPCs, and high for skin squamous cell cancer (24·58 for in situ and 7·63 for invasive), Merkel cell carcinoma (14·36), Hodgkin lymphoma (7·16) and Kaposi sarcoma (6·76). Conversely, 15 CLL cancer pairs were reciprocally increased. The increased risks were reciprocal for ALL and four cancers. RR for ALL was 15·35 after myeloid neoplasia. HCL showed reciprocally increased RRs with non‐Hodgkin lymphoma and melanoma. The concordance between RRs for bi‐directional associations between CLL and different cancers, and HCL and different cancers was highly significant. For CLL (also for HCL), the bi‐directional risks with skin cancers and other immune‐related cancers suggest the probable involvement of immune dysfunction. For ALL, treatment may contribute to risks of multiple SPCs. Increased risk of ALL after haematological neoplasms may indicate bone marrow dysfunction. These findings may help guide treatment decisions and prognostic assessment.

show abstract

“…The monitoring of the evolution of our patient involves the early detection of possible infections, autoimmune diseases [23] or a new malignancy [24]. Patients with HCL, who have a dysfunctional immune response [23], are prone to develop one or more of these complications.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with HCL, who have a dysfunctional immune response [23], are prone to develop one or more of these complications. In a survey made on 487 patients with HCL, 18% presented a familial history of cancers, 8% were diagnosed with malignancies before HCL diagnosis and 10% developed a second cancer after HCL was diagnosed [24].…”

Section: Discussionmentioning

confidence: 99%

Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?

Mihăilă¹

2015

Int J Immunother Cancer Res

View full text Add to dashboard Cite

Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeutic horizons. Case presentation:We present a female patient to which the disease has been monitored for 14 years, during which she has been treated with alpha-interferon, cladribine and rituximab. The monitorization and conduct of such patients are discussed, and an analysis of the therapeutic possibilities at this stage is performed, which can be useful for physicians and researchers. Conclusion:An individual assessment of patient at diagnosis and during evolution is needed to determine which drug or drug combination is indicated and how many therapeutic lines are needed.

show abstract

Autoimmune disorders in patients with hairy cell leukemia: are they more common than previously thought?

Cited by 13 publications

References 31 publications

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia

Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?

Contact Info

Product

Resources

About